ResMed, Inc. RMD has unveiled its AirCurve 11 series devices, the latest bilevel devices utilizing two levels of support – inspiratory positive airway pressure and expiratory positive airway pressure. Integrated with digital technology, this innovation aims to simplify sleep apnea treatment for healthcare providers and improve therapy compliance among patients.
Leveraging ResMed’s industry-leading AirSense 11 technology, the AirCurve 11 series expands the options available to doctors and healthcare professionals in selecting the most effective treatment for sleep apnea patients.
AirCurve 11 Bilevel Devices
AirCurve 11 sets a new standard as ResMed’s advanced adaptive servo-ventilation device, replicating the patient’s natural breathing pattern. This functionality is critical for individuals with central sleep apnea, obstructive sleep apnea, mixed apneas, or periodic breathing.
The device, designed to enhance comfort and compliance, provides higher pressure during inhalation and lower pressure during exhalation. This unique feature enables the device to better synchronize with the patient’s normal breathing rhythm.
Image Source: Zacks Investment Research
The AirCurve 11 series is equipped with a robust combination of features and settings to offer advanced support to patients and providers. This includes integrated cellular and Bluetooth communication for secure and automated data transmission to the cloud, accessible via AirView and myAir. Additionally, the device features an integrated heated humidifier that can be automatically controlled using the Climate Control feature or manually by the user.
Benefits of the Launch
The integration of ResMed’s new AirCurve11 series with myAir and AirView digital health apps has significantly increased patient compliance from 70% to 87%, enhancing comfort and support during therapy.
According to management, ResMed’s product development approach is centered on prioritizing patient well-being. This customer-centric approach drives the company’s commitment to launching products like AirCurve 11, enabling individuals to effectively manage sleep apnea from the comfort of their homes.
Industry Prospects
A report by Grand View Research indicates that the global sleep apnea devices market size was valued at $4.50 billion in 2023 and is projected to achieve a CAGR of 6.2% by 2030. The increasing susceptibility of the growing geriatric population to sleep apnea is anticipated to drive the adoption of sleep apnea devices.
Progress Within Sleep Apnea Treatment Business
ResMed is capitalizing on traditional healthcare channels and investing in cost-effective social media-driven demand generation campaigns to guide concerned consumers towards screening, diagnostic, treatment, and management pathways for sleep and breathing disorders. The company is closely monitoring new-patient starts in its physician and provider-based ecosystem, which now encompasses over 26 million patient records, as well as new-user starts in the myAir app.
Furthermore, ResMed reported strong patient adoption of the myAir app, with adoption rates by new patients on therapy with AirSense 11 exceeding double those of AirSense 10.
The company also recently commenced an in-market trial of a ResMed-developed generative AI product, serving as a digital concierge to assist individuals in navigating the search for sleep-related information.
Price Performance
Over the past year, ResMed’s shares have declined 13.8%, in contrast to the industry’s 3.2% growth.
Zacks Rank and Key Picks
Presently, RMD holds a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering in the broader medical space include Universal Health Services UHS, Integer Holdings Corporation ITGR, and DaVita DVA.
Universal Health Services, currently holding a Zacks Rank #2 (Buy), is estimated to achieve a growth rate of 4.4% for 2024. UHS has consistently surpassed earnings estimates in the preceding four quarters, yielding an average surprise of 5.47%. More information on promising Zacks #1 Rank (Strong Buy) stocks can be found here.
UHS’ shares have surged by 25% in the last six months, outperforming the industry’s 15% growth.
Integer Holdings, presently holding a Zacks Rank of 2, is estimated to achieve a long-term growth rate of 15.8%. ITGR has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 11.9%.
Integer Holdings’ shares have soared by 47.2% in the last year, outperforming the industry’s 3.9% growth.
Estimates for DaVita’s 2023 earnings per share have remained constant at $8.07 in the past 30 days. The company’s shares have climbed by 37.9% in the last year, surpassing the industry’s 11.2% growth. DaVita has consistently exceeded earnings estimates, with an average surprise of 36.6%. In the most recent quarter, it delivered an earnings surprise of 48.4%.
Zacks Names #1 Semiconductor Stock
It’s only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it’s positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
